drugset / Trial / NCT07121829
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a subprotocol of Master Protocol DAY101-102 and is a Phase 1b/2, multi-center, open label subprotocol of participants ≥12 years of age, with recurrent or progressive solid tumors with alterations in the key proteins of the MAPK pathway, such as tumors that harbor RAS or RAF alterations. \*Note: Study concluded as Phase 1b only.
Timeline
- Start
- 2022-05-02
- Primary completion
- 2024-12-18
- Completion
- 2024-12-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pimasertib | Small molecule | — | Oral |
| Subject | Tovorafenib | Small molecule | — | Oral |